Abbott Laboratories reports 10% EPS growth for fiscal year 2025
Abbott Laboratories reported full-year 2025 adjusted diluted earnings per share (EPS) of $5.15, a 10% increase. The company forecast continued strong performance for 2026, projecting organic sales growth of 6.5% to 7.5%.
Abbott Laboratories announced its full-year 2025 results, with adjusted diluted earnings per share (EPS) reaching $5.15, representing a 10% increase. For the fourth quarter, adjusted diluted EPS grew 12% to $1.50.
Total sales for the full year 2025 were $44.3 billion, an organic increase of 6.7%. Fourth-quarter sales stood at $11.5 billion, showing 3.8% organic growth when excluding COVID-19 testing sales. The company noted that Medical Devices and Established Pharmaceuticals led this growth.
Medical Devices, in particular, experienced organic sales growth of 10.4% in the fourth quarter, marking the twelfth consecutive quarter of double-digit expansion. Key areas contributing to this growth included electrophysiology, heart failure, diabetes care, and rhythm management.
Looking ahead, Abbott issued guidance for 2026, projecting organic sales growth between 6.5% and 7.5%. The company anticipates adjusted diluted EPS to be in the range of $5.55 to $5.80, representing 10% growth at the midpoint. Recent product approvals and the planned acquisition of Exact Sciences are expected to support future performance.